NCT05277363 is a clinical trial of None (Observational study) in Leigh Syndrome, sponsored by Taysha Gene Therapies, Inc..

Who is sponsoring NCT05277363?

NCT05277363 is sponsored by Taysha Gene Therapies, Inc..

What drugs are being tested in NCT05277363?

Interventions in NCT05277363: None (Observational study).

What condition does NCT05277363 study?

NCT05277363 studies Leigh Syndrome.

Is NCT05277363 still recruiting?

NCT05277363 is currently withdrawn. Last updated 20 May 2022.

Last reviewed 2022-05-20 · How we verify

NCT05277363

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Natural Course of SURF1 Deficiency

Withdrawn Last updated 20 May 2022

What this trial tests

trial testing None (Observational study) in Leigh Syndrome. Withdrawn.

Timeline

4 May 2022

Primary endpoint
4 May 2022

4 May 2022

Quick facts

Lead sponsor	Taysha Gene Therapies, Inc.
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	4 May 2022
Primary completion	4 May 2022
Estimated completion	4 May 2022
Sites	1 location across United States

Drugs / interventions tested

None (Observational study)

Conditions studied

Leigh Syndrome — all drugs for Leigh Syndrome →

Sponsor

Taysha Gene Therapies, Inc. — full company profile →

Who can join

Under 18, any sex, with Leigh Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to prospectively and systematically collect standardized clinical information, to describe important features of the disease course of SURF1 deficiency. These include but are not limited to symptomatology, clinical course, and risk factors for severe disease and complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of None (Observational study)

Trials testing the same drug.

NCT07346768 — Evaluation of Anterior Neck Ultrasound in Predicting Difficult Airway in Obese Patients · not yet recruiting
NCT07141277 — GRANITE: Airsupra Effectiveness in the Real World · recruiting
NCT06222957 — The Effects of HER2 Receptor Signaling on Human Brown Fat Activity · recruiting
NCT06527872 — Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN · recruiting
NCT06607068 — Assessment of Taurine Concentration in Older Women With/Without Obesity And With/Without Type 2 Diabetes Mellitus · active not recruiting

Other recruiting trials for Leigh Syndrome

Currently open trials in the same condition.

NCT03137355 — The International Registry for Leigh Syndrome · recruiting

Other Taysha Gene Therapies, Inc. trials

Trials by the same sponsor.

NCT06152237 — Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05277363 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taysha Gene Therapies, Inc.
Last refreshed: 20 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05277363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing